Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 354 participants.
Also called NCT05425745
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 354 participants
- Sponsor
- Registry
-
NCT05425745
-
- Other papers using this trial's data
- Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Georgia, Netherlands, Norway, Poland, South Africa, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05425745. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-25 (actual); primary completion 2024-05-28 (actual). Results posted on 2025-06-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
- Acronym
- BROOKLYN
- Condition
- Dyslipidemias
- Condition
- High Cholesterol
- Condition
- Hypercholesterolemia
- Condition
- Familial Hypercholesterolemia
- Condition
- Lipid Metabolism Disorder
- Condition
- Metabolic Disease
- Condition
- Lipid Metabolism, Inborn Errors
- Condition
- Genetic Disease, Inborn
- Condition
- Hyperlipoproteinemias
- Intervention (Drug)
- Obicetrapib
- Intervention (Drug)
- Placebo
- Lead sponsor
- NewAmsterdam Pharma
Record details
- Record id
cardio:ct-nct05425745- Content hash
256c74b3172523144a654dd72a48322e30a1dfa9a4f5fee2fa91571bc8628621